Building on TIL therapy while advancing off-the-shelf cell therapies and in-vivo CAR-T.
Autologous therapies are complex to manufacture, slow to deliver, costly and difficult to standardise at scale.
Cell therapy has transformed blood cancers, while solid tumours remain a much larger unmet clinical need.
7 clinical assets. 1 pivotal study. 4 approved INDs.